These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 34738847)

  • 1. Higher Expression of
    Chen C; Chen Z; Chio CL; Zhao Y; Li Y; Liu Z; Jin Z; Wu X; Wei W; Zhao Q; Li Y
    Technol Cancer Res Treat; 2021; 20():15330338211052152. PubMed ID: 34738847
    [No Abstract]   [Full Text] [Related]  

  • 2. Single nucleotide polymorphism in the mutational hotspot of WT1 predicts a favorable outcome in patients with cytogenetically normal acute myeloid leukemia.
    Damm F; Heuser M; Morgan M; Yun H; Grosshennig A; Göhring G; Schlegelberger B; Döhner K; Ottmann O; Lübbert M; Heit W; Kanz L; Schlimok G; Raghavachar A; Fiedler W; Kirchner H; Döhner H; Heil G; Ganser A; Krauter J
    J Clin Oncol; 2010 Feb; 28(4):578-85. PubMed ID: 20038731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Wilms Tumor 1 Expression at Diagnosis Correlates With Genetic Abnormalities and Polymorphism But Is Not Independently Prognostic in Acute Myelogenous Leukemia: A Hokkaido Leukemia Net Study.
    Hidaka D; Onozawa M; Hashiguchi J; Miyashita N; Kasahara K; Fujisawa S; Hayase E; Okada K; Shiratori S; Goto H; Sugita J; Nakagawa M; Hashimoto D; Kahata K; Endo T; Yamamoto S; Tsutsumi Y; Haseyama Y; Nagashima T; Mori A; Ota S; Sakai H; Ishihara T; Imai K; Miyagishima T; Kakinoki Y; Kurosawa M; Kobayashi H; Iwasaki H; Shimizu C; Kondo T; Teshima T
    Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):e469-e479. PubMed ID: 30082223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpression of Wilms tumor 1 gene as a negative prognostic indicator in acute myeloid leukemia.
    Lyu X; Xin Y; Mi R; Ding J; Wang X; Hu J; Fan R; Wei X; Song Y; Zhao RY
    PLoS One; 2014; 9(3):e92470. PubMed ID: 24667279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence and Prognostic Impact of Wilms' Tumor 1 (WT1) Gene, Including SNP rs16754 in Cytogenetically Normal Acute Myeloblastic Leukemia (CN-AML): An Iranian Experience.
    Toogeh G; Ramzi M; Faranoush M; Amirizadeh N; Haghpanah S; Moghadam M; Cohan N
    Clin Lymphoma Myeloma Leuk; 2016 Mar; 16(3):e21-6. PubMed ID: 26725263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study.
    Paschka P; Marcucci G; Ruppert AS; Whitman SP; Mrózek K; Maharry K; Langer C; Baldus CD; Zhao W; Powell BL; Baer MR; Carroll AJ; Caligiuri MA; Kolitz JE; Larson RA; Bloomfield CD
    J Clin Oncol; 2008 Oct; 26(28):4595-602. PubMed ID: 18559874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High NCALD expression predicts poor prognosis of cytogenetic normal acute myeloid leukemia.
    Song Y; Zhang W; He X; Liu X; Yang P; Wang J; Hu K; Liu W; Zhang X; Jing H; Yuan X
    J Transl Med; 2019 May; 17(1):166. PubMed ID: 31109331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel 5-gene prognostic signature to improve risk stratification of cytogenetically normal acute myeloid leukemia.
    Deng C; Zeng T; Zhu P; Zhao S; Huang Z; Huang W; Zhang W; Huang X; Fu L
    J Cancer Res Clin Oncol; 2023 Sep; 149(12):10015-10025. PubMed ID: 37258721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of Wilms Tumor 1 Gene Expression as a Reliable Marker for Prognosis and Minimal Residual Disease Monitoring in Acute Myeloid Leukemia With Normal Karyotype Patients.
    Marjanovic I; Karan-Djurasevic T; Ugrin M; Virijevic M; Vidovic A; Tomin D; Suvajdzic Vukovic N; Pavlovic S; Tosic N
    Clin Lymphoma Myeloma Leuk; 2017 May; 17(5):312-319. PubMed ID: 28163010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study.
    Becker H; Marcucci G; Maharry K; Radmacher MD; Mrózek K; Margeson D; Whitman SP; Wu YZ; Schwind S; Paschka P; Powell BL; Carter TH; Kolitz JE; Wetzler M; Carroll AJ; Baer MR; Caligiuri MA; Larson RA; Bloomfield CD
    J Clin Oncol; 2010 Feb; 28(4):596-604. PubMed ID: 20026798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High prognostic value of pre-allogeneic stem cell transplantation minimal residual disease detection by WT1 gene expression in AML transplanted in cytologic complete remission.
    Candoni A; De Marchi F; Zannier ME; Lazzarotto D; Filì C; Dubbini MV; Rabassi N; Toffoletti E; Lau BW; Fanin R
    Leuk Res; 2017 Dec; 63():22-27. PubMed ID: 29096332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Prognostic Significance of PDE7B in Cytogenetically Normal Acute Myeloid Leukemia.
    Cao L; Zhang W; Liu X; Yang P; Wang J; Hu K; Zhang X; Liu W; He X; Jing H; Yuan X
    Sci Rep; 2019 Nov; 9(1):16991. PubMed ID: 31740742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical relevance of Wilms tumor 1 gene mutations in childhood acute myeloid leukemia.
    Hollink IH; van den Heuvel-Eibrink MM; Zimmermann M; Balgobind BV; Arentsen-Peters ST; Alders M; Willasch A; Kaspers GJ; Trka J; Baruchel A; de Graaf SS; Creutzig U; Pieters R; Reinhardt D; Zwaan CM
    Blood; 2009 Jun; 113(23):5951-60. PubMed ID: 19171881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High expression of inositol 1,4,5-trisphosphate receptor, type 2 (ITPR2) as a novel biomarker for worse prognosis in cytogenetically normal acute myeloid leukemia.
    Shi JL; Fu L; Wang WD
    Oncotarget; 2015 Mar; 6(7):5299-309. PubMed ID: 25779662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High expression of CD56 may be associated with favorable overall survival in intermediate-risk acute myeloid leukemia.
    Chen C; Chio CL; Zeng H; Li Y
    Hematology; 2021 Dec; 26(1):210-214. PubMed ID: 33594945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serial measurement of WT1 expression and decrement ratio until hematopoietic cell transplantation as a marker of residual disease in patients with cytogenetically normal acute myelogenous leukemia.
    Yoon JH; Kim HJ; Shin SH; Yahng SA; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Park CW; Lim JH
    Biol Blood Marrow Transplant; 2013 Jun; 19(6):958-66. PubMed ID: 23542687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High WT1 expression predicted induction chemotherapy failure in acute myeloid leukemia patients with non-favorable cytogenetic risk.
    Xu N; Chen WM; Li LD; Long LY; Wang X; Jiang Q; Jiang H; Huang XJ; Qin YZ
    Clin Exp Med; 2023 Oct; 23(6):2629-2638. PubMed ID: 36637581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia: a study of the German-Austrian AML Study Group.
    Gaidzik VI; Schlenk RF; Moschny S; Becker A; Bullinger L; Corbacioglu A; Krauter J; Schlegelberger B; Ganser A; Döhner H; Döhner K;
    Blood; 2009 May; 113(19):4505-11. PubMed ID: 19221039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic impact of PRDM16 expression in acute myeloid leukemia with normal cytogenetics.
    Xiang X; Lu Q; Xu X; Cai P; Chen S; Pan J; Zeng Z
    Hematology; 2022 Dec; 27(1):499-505. PubMed ID: 35473465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic Impact of WT-1 and Survivin Gene Expression in Acute Myeloid Leukemia Patients.
    Adnan-Awad S; Meligui YME; Salem SE; Salaheldin O; Ayoub MA; Kamel MM
    Clin Lab; 2019 Apr; 65(4):. PubMed ID: 30969080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.